Literature DB >> 26872891

Increased expressions of claudin 4 and 7 in atypical adenomatous hyperplasia and adenocarcinoma of the lung.

Gen Yamada1, Masaki Murata2, Akira Takasawa2, Masanori Nojima3, Yuki Mori4, Norimasa Sawada2, Hiroki Takahashi4.   

Abstract

Abnormal expression of claudin (Cldn), the main constituent of tight junctions, may play a crucial role in carcinogenesis. To elucidate these abnormalities of tight junctions in lung adenocarcinoma during carcinogenesis, we examined immunohistochemical expressions of Cldn4 and Cldn7 in human lung resection materials. Lung resection specimens from 86 patients were studied, including 16 atypical adenomatous hyperplasia (AAH), 19 adenocarcinoma in situ (AIS), 32 invasive adenocarcinoma (ADC), 5 AIS with AAH, 2 ADC with AAH, 10 ADC with AIS, and 2 ADC with AIS and AAH. The immunohistochemical staining (IHC) score was defined for both the extent and intensity of staining. IHC score for Cldn4 in AIS and ADC was significantly higher than that in alveolar epithelium (AE) and AAH (p < 0.001 for both). In addition, the AAH score was significantly higher than that in AE (p < 0.001). The Cldn7 score in ADC was significantly increased compared with AE and AAH (p < 0.001 for both). These results suggested that increase of Cldn4-expression may be involved in early molecular events during carcinogenesis of adenocarcinoma, whereas increase of Cldn7-expression may be associated with tumor invasion or progression.

Entities:  

Keywords:  Adenocarcinoma in situ; Atypical adenomatous hyperplasia; Invasive adenocarcinoma; Tight junction molecule

Mesh:

Substances:

Year:  2016        PMID: 26872891     DOI: 10.1007/s00795-016-0135-6

Source DB:  PubMed          Journal:  Med Mol Morphol        ISSN: 1860-1499            Impact factor:   2.309


  31 in total

1.  Analysis of clinical characteristics and differential diagnosis of the lung biopsy specimens in 99 adenocarcinoma cases and 111 squamous cell carcinoma cases: utility of an immunohistochemical panel containing CK5/6, CK34βE12, p63, CK7 and TTF-1.

Authors:  Xiao-Yan Xu; Guang-Ying Yang; Jin-Hua Yang; Jun Li
Journal:  Pathol Res Pract       Date:  2014-07-01       Impact factor: 3.250

2.  Synchronous double primary lung carcinomas associated with multiple atypical adenomatous hyperplasia.

Authors:  K Suzuki; K Takahashi; J Yoshida; M Nishimura; T Yokose; Y Nishiwaki; K Nagai
Journal:  Lung Cancer       Date:  1998-02       Impact factor: 5.705

Review 3.  Atypical adenomatous hyperplasia of the lung: a probable forerunner in the development of adenocarcinoma of the lung.

Authors:  M Mori; S K Rao; H H Popper; P T Cagle; A E Fraire
Journal:  Mod Pathol       Date:  2001-02       Impact factor: 7.842

4.  Claudin-4-targeted therapy using Clostridium perfringens enterotoxin for prostate cancer.

Authors:  Toshihiro Maeda; Masaki Murata; Hideki Chiba; Akira Takasawa; Satoshi Tanaka; Takashi Kojima; Naoya Masumori; Taiji Tsukamoto; Norimasa Sawada
Journal:  Prostate       Date:  2011-06-08       Impact factor: 4.104

5.  Regulation of tight junctions by sex hormones in normal human endometrial epithelial cells and uterus cancer cell line Sawano.

Authors:  Masayuki Someya; Takashi Kojima; Marie Ogawa; Takafumi Ninomiya; Kazuaki Nomura; Akira Takasawa; Masaki Murata; Satoshi Tanaka; Tsuyoshi Saito; Norimasa Sawada
Journal:  Cell Tissue Res       Date:  2013-07-03       Impact factor: 5.249

6.  Expression levels of protein kinase C-alpha in non-small-cell lung cancer.

Authors:  Michael Lahn; Chen Su; Shuyu Li; Marcio Chedid; Kimberly R Hanna; Jeremy R Graff; George E Sandusky; Doreen Ma; Clet Niyikiza; Karen L Sundell; William J John; Thomas J Giordano; David G Beer; Blake M Paterson; Eric Wen Su; Thomas F Bumol
Journal:  Clin Lung Cancer       Date:  2004-11       Impact factor: 4.785

7.  Epidermal growth factor receptor mutation and p53 overexpression during the multistage progression of small adenocarcinoma of the lung.

Authors:  Seol Bong Yoo; Jin-Haeng Chung; Hyun Ju Lee; Choon-Taek Lee; Sanghoon Jheon; Sook Whan Sung
Journal:  J Thorac Oncol       Date:  2010-07       Impact factor: 15.609

8.  Proliferative potential and p53 overexpression in precursor and early stage lesions of bronchioloalveolar lung carcinoma.

Authors:  H Kitamura; Y Kameda; N Nakamura; Y Nakatani; Y Inayama; M Iida; K Noda; N Ogawa; T Shibagaki; M Kanisawa
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

9.  Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma.

Authors:  T Ueno; S Linder; G Elmberger
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

Review 10.  Tight junction-related human diseases.

Authors:  Norimasa Sawada
Journal:  Pathol Int       Date:  2013-01-07       Impact factor: 2.534

View more
  5 in total

Review 1.  Claudins in cancer: bench to bedside.

Authors:  Makoto Osanai; Akira Takasawa; Masaki Murata; Norimasa Sawada
Journal:  Pflugers Arch       Date:  2016-09-13       Impact factor: 3.657

2.  Integrated analysis of dosage effect lncRNAs in lung adenocarcinoma based on comprehensive network.

Authors:  Yunzhen Wei; Zichuang Yan; Cheng Wu; Qiang Zhang; Yinling Zhu; Kun Li; Yan Xu
Journal:  Oncotarget       Date:  2017-08-03

3.  Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma Using a Radiolabelled Anti-Claudin-4 Monoclonal Antibody.

Authors:  Julia Baguña Torres; James C Knight; Michael J Mosley; Veerle Kersemans; Sofia Koustoulidou; Danny Allen; Paul Kinchesh; Sean Smart; Bart Cornelissen
Journal:  Mol Imaging Biol       Date:  2018-04       Impact factor: 3.488

4.  Tight Junction Protein Claudin-12 Is Involved in Cell Migration during Metastasis.

Authors:  Desislava Kolchakova; Dzhemal Moten; Tsvetelina Batsalova; Balik Dzhambazov
Journal:  Biomolecules       Date:  2021-04-25

Review 5.  Emerging clinical significance of claudin-7 in colorectal cancer: a review.

Authors:  Kun Wang; Chang Xu; Wenjing Li; Lei Ding
Journal:  Cancer Manag Res       Date:  2018-09-20       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.